Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Autolus Therapeutics plcNASDAQ: AUTL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $2.7M rose 18.5% year over year, ahead of the +16.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 41.0% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Depreciation & amortization amounted to 13.0% of revenue in FY2025, down 63.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of +16.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 9.81M USD
- Year-over-year change
- +27.2%
- 4-year CAGR
- +3.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.81M | +27.2% |
| FY2024 | 2024-12-31 | 7.72M | +17.5% |
| FY2023 | 2023-12-31 | 6.57M | -11.5% |
| FY2022 | 2022-12-31 | 7.42M | -12.2% |
| FY2021 | 2021-12-31 | 8.46M | — |
Depreciation & Amortization vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 depreciation & amortization of $12.18M is the 4th largest of the 10 companies compared; the peer median is $11.71M.
- Its year-over-year change of +16.3% is the 2nd highest of 10, against a peer median of -28.6%.
- Depreciation & amortization amounts to 13.2% of revenue for AUTL, versus a peer median of 27.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.27M | +111.9% | +16.3% | 3.7% | |
| LTM Mar 2026 | $19.68M | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $12.18M | +16.3% | +9.8% | 13.2% | |
| LTM Mar 2026 | $12.13M | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $11.71M | -33.0% | -12.3% | 185.5% | |
| LTM Mar 2026 | $10.43M | -42.2% | -11.2% | 33645.2% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $175K | -96.8% | -25.1% | 0.8% | |
| Peer median (excluding AUTL) | $11.71M | -28.6% | -4.7% | 27.9% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (287.53M) |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.81M |
| Deferred Income Tax | (72K) | (268K) | (986K) | (185K) | (286K) |
| Stock-Based Compensation | 9.94M | 12.01M | 11.2M | 15.47M | 14.44M |
| Change in Working Capital | 4.14M | 3.97M | 292K | (23.66M) | (52.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (24.21M) |
| Inventory | 0 | 0 | 0 | (4.23M) | (40.34M) |
| Accounts Payables | (1.82M) | 22K | (509K) | 1.59M | 1.3M |
| Other Working Capital | 5.95M | 3.95M | 801K | (21.02M) | 11.14M |
| Other Non-Cash Items | 1.77M | 13.4M | 45.72M | 15.04M | 32.1M |
| Operating Cash Flow | (117.86M) | (112.31M) | (145.59M) | (206.27M) | (283.57M) |
| Capital Expenditures | (8.86M) | (10.84M) | (10.99M) | (34.82M) | (27.13M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (359.73M) | (242.62M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 428.21M |
| Other Investing Activities | 0 | 0 | 0 | (12.74M) | (8.09M) |
| Investing Cash Flow | (8.86M) | (10.84M) | (10.99M) | (394.55M) | 158.46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 245.9M | 163.85M | 0 | 549.98M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 38.16M | 59.76M | (883K) | 39.58M | (4.34M) |
| Financing Cash Flow | 284.06M | 223.61M | (883K) | 589.55M | (4.34M) |
| Effect of Forex Changes | (754K) | (28.38M) | 15.03M | (261K) | 6.28M |
| Net Change in Cash | 156.59M | 72.09M | (142.43M) | (11.53M) | (123.17M) |
| Free Cash Flow | (126.72M) | (123.15M) | (156.57M) | (241.09M) | (310.7M) |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.